Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently

Diabetes Research and Clinical Practice

Volumn 93, Issue 1, 2011, Pages 10-16

  Li, Xuesong ^a   Fan, Xiaofang ^a   Ren, Fengdong ^a   Zhang, Yu ^a   Shen, Chunfang ^a   Ren, Guoguang ^a   Sun, Jue ^a   Zhang, Ning ^a   Wang, Weiqing ^b   Ning, Guang ^b   Yang, Jialin ^a  

^a The Central Hospital of Minhang District   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Fibroblast growth factor 21; Nonalcoholic fatty liver disease; Type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHOLESTEROL; FIBROBLAST GROWTH FACTOR 21; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; ORAL GLUCOSE TOLERANCE TEST; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO;

ADULT; AGED; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MALE; MIDDLE AGED;

EID: 79960564639     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.02.034     Document Type: Article

References (23)

1. Nishimura T., Nakatake Y., Konishi M., Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 2000, 1492(June (1)):203-206.
2. Huang X., Yu C., Jin C., Yang C., Xie R., Cao D., et al. Forced expression of hepatocyte-specific fibroblast growth factor-21 delays initiation of chemically-induced hepatocarcinogenesis. Mol Carcinog 2006, (December):42.
3. Wente W., Efanov A.M., Brenner M., Kharitonenkov A., Koster A., Sandusky G.E., et al. Fibroblast growth factor-21 improves pancreatic β-cell function and survival by activation of extracellular signal regulated kinase 1/2 and Akt signaling pathways. Diabetes 2006, 55(September (9)):2470-2478.
4. Kharitonenkov A., Shiyanova T.L., Koester A., Ford A.M., Micanovic R., Galbreath E.J., et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005, 115(June (6)):1627-1635.
5. Kharitonenkov A, Shanafelt A.B. Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases. BioDrugs 2008, 22(1):37-44.
6. Zhang X., Yeung D.C.Y., Karpisek M., Stejskal D., Zhou Z.G., Liu F., et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008, 57:1246-1253.
7. Li H., Bao Y., Xu A., Pan X.P., Lu J.X., Wu H.Y., et al. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and γ-glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab 2009, 94:2151-2156.
8. Chavez A.O., Folli F., Molina-Carrion M., Defronzo R., Abdul-Ghani M.A., Tripathy D. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 2009, 32:1542-1546.
9. Kogiso T., Moriyoshi Y., Shimizu S., Nagahara H., Shiratori K. High-sensitivity C-reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the Akaike Information Criterion scoring system in the general Japanese population. J Gastroenterol 2009, 44(4):313-321.
10. Riquelme A., Arrese M., Soza A., Morales A., Baudrand R., Pérez-Ayuso R.M., et al. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver Int 2009, 29(January (1)):82-88.
11. Frohlich M., Imhof A., Berg G., Hutchinson W.L., Pepys M.B., Boeing H., et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000, 23:1835-1839.
12. Farrell G.C., Chitturi S., Lau G.K., Sollano J.D. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol 2007, 22:775-777. Asia-Pacific Working Party on NAFLD.
13. Kharitonenkov A., Wroblewski V.J., Koester A., Chen Y.F., Clutinger C.K., Tigno X.T., et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007, 148:774-781.
14. Chen W.-W., Li L., Yang G.-Y., Li K., Qi X.-Y., Zhu W., et al. Circulating FGF-21 levels in normal subjects and in newly diagnose patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2008, 116:65-68.
15. Yilmaz Y., Eren F., Yonal O., Kurt R., Aktas B., Celikel C.A., et al. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest 2010, 40(October (10)):887-892.
16. Bahceci M., Tuzcu A., Ogun C., Canoruc N., Iltimur K., Aslan C. Is serum C-reactive protein concentration correlated with HbA1c and insulin resistance in type 2 diabetic patients men with or without coronary heart disease. J Endocrinol Invest 2005, 28:145-150.
17. Anan F., Takahashi N., Nakagawa M., Ooie T., Saikawa T., Yoshimatsu H. High-sensitivity C-reactive protein is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients. Metabolism 2005, 54:552-558.
18. Koh J.H., Shin Y.G., Nam S.M., Lee M.Y., Chung C.H., Shin J.Y. Serum adipocyte fatty acid-binding protein levels are associated with nonalcoholic fatty liver disease in type 2 diabetic patients. Diabetes Care 2009, 32:147-152.
19. Xu A., Tso A.W., Cheung B.M., Wang Y., Wat N.M., Fong C.H. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 2007, 115:1537-1543.
20. Badman M.K., Pissios P., Kennedy A.R., Koukos G., Flier J.S., Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007, 5:426-437.
21. Moyers Y.S., Shiyanova T.L., Mehrbod F., Dunbar J.D., Noblitt T.W., Otto K.A., et al. Molecular determinants of FGF-21 activity: synergy and cross-talk with PPARγ signaling. J Cell Physiol 2007, 210(January (1)):1-6.
22. Mohanty P., Aljada A., Hofmeyer G.H., Hofmeyer D., Tripathy D., Syed T., et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004, 89:2728-2735.
23. Haffner S.M., Greenberg A.S., Weston W.M., Chen H., Williams K., Freed M.I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002, 106:679-684.